Immunovant (IMVT) Current Leases (2020 - 2026)
Immunovant (IMVT) reported Current Leases of $72000.0 for Q1 2026, down 26.53% on a YoY basis from $98000.0 in Q1 2025, and down 26.53% quarter-over-quarter from $98000.0 in Q1 2025.
Immunovant (IMVT) Current Leases (2020 - 2026) Analysis & Trends
Immunovant has reported Current Leases for 7 years, with the latest figure at $72000.0 in Q1 2026.
- For the quarter ending Q1 2026, Current Leases fell 26.53% year-over-year to $72000.0; the trailing twelve-month figure through Mar 2026 stood at $72000.0 (down 26.53% YoY), and the FY2026 full-year result was $72000.0, down 26.53% from the prior year.
- Current Leases for Q1 2026 stood at $72000.0, down from $98000.0 in the prior quarter.
- The five-year high for Current Leases was $1.2 million in Q4 2022, with the low at $23000.0 in Q4 2024.
- Historically, Current Leases has averaged $582785.7 across 5 years, with a median of $460000.0 in 2023.
- Annual changes were most pronounced in 2022 — Current Leases climbed 11.68% — and 2024, when it tumbled 92.49%.
- Immunovant's Current Leases stood at $1.2 million in 2022, then sank by 74.61% to $306000.0 in 2023, then sank by 92.48% to $23000.0 in 2024, then soared by 326.09% to $98000.0 in 2025, then retreated by 26.53% to $72000.0 in 2026.
- The last three Current Leases figures came in at $72000.0 (Q1 2026), $98000.0 (Q1 2025), and $23000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 83,991.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 7.40 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Immunovant | 5.71 Bn | 5.71 Bn | - | 72,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 72,000.00 |
| Mar 31, 2025 | 98,000.00 |
| Dec 31, 2024 | 23,000.00 |
| Sep 30, 2024 | 47,000.00 |
| Jun 30, 2024 | 69,000.00 |
| Mar 31, 2024 | 138,000.00 |
| Dec 31, 2023 | 306,000.00 |
| Sep 30, 2023 | 614,000.00 |
| Jun 30, 2023 | 919,000.00 |
| Mar 31, 2023 | 1.17 Mn |
| Dec 31, 2022 | 1.21 Mn |
| Sep 30, 2022 | 1.19 Mn |
| Jun 30, 2022 | 1.17 Mn |
| Mar 31, 2022 | 1.15 Mn |
| Dec 31, 2021 | 1.08 Mn |
| Sep 30, 2021 | 1.08 Mn |
| Jun 30, 2021 | 1.09 Mn |
| Mar 31, 2021 | 1.18 Mn |
| Dec 31, 2020 | 1.10 Mn |
| Sep 30, 2020 | 1.10 Mn |